Eric SchadtChair, Department of Genetics & Genomic Sciences Mount Sinai School of Medicine
Michael SnyderDirector, Center for Genomics and Personalized Medicine Stanford University School of Medicine
Eric LaiSenior Vice President & Head of Pharmacogenomics Takeda
Catherine TribouleyHead of Biomarker and Pathway Analysis, Inflammation Roche
Recent ENCODE data has further highlighted the importance of genomic research in the ongoing development of personalized treatments. This new wave of understanding the human genome and its role in drug response is having implications far beyond the halls of academia, and is having a hugely significant effect on the way we view personalized drug development
If you’re reading this, you’re probably already tapping into the huge commercial potential of PGx. But you’ll also agree that there are many unanswered questions. For instance, the integration of genetics into drug discovery and development. How pharmacogenomics can better influence the course of clinical development? And of course, how to effectively and practically utilize genomic information now?
More effectively predict patient response
Make better use of genetic data
Develop better drugs
Plus over 8 hours of dedicated networking opportunities, meaning you get to spend quality time with the key players in the PGx field
"Having participated in several more academic PGx meetings, and based on my previous experience at professional conference, my expectations for the meeting last week were not high. I can assure you that they were far exceeded. I was impressed with the format, topics and speakers in the meeting, and the ability to contrast viewpoints and approaches that other companies are taking to address the role of PGx in personalized medicine. My colleagues and I have been providing glowing reports upon our return." GlaxoSmithKline
"Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues..." X Mahfoudi, Director, Head Oncology Business Opportunities, Sanofi Aventis
“One of the best meetings I’ve attended. Outstanding!” Director, Merck